Sanofi (BIT:1SAN)
Italy · Delayed Price · Currency is EUR | Market Cap | 86.19B -16.0% |
| Revenue (ttm) | 48.92B +7.0% |
| Net Income | 3.96B -56.6% |
| EPS | 3.26 -55.6% |
| Shares Out | n/a |
| PE Ratio | 21.78 |
| Forward PE | 8.18 |
| Dividend | 4.12 (5.82%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 7,398 |
| Open | 70.87 |
| Previous Close | 73.24 |
| Day's Range | 69.79 - 71.28 |
| 52-Week Range | 69.79 - 90.78 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 nov... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sanofi price target lowered to EUR 75 from EUR 800 at RBC Capital
RBC Capital lowered the firm’s price target on Sanofi (SNY) to EUR 75 from EUR 800 and keeps a Sector Perform rating on the shares ahead of its Q3 results.
Sanofi, PCPA Sign LOI For Dupixent Across Four Additional Indications
(RTTNews) - Sanofi (SNY) said Thursday it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) and signed a letter of intent, or LOI for Dupixent across four additional indi...
Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Sanofi, pCPA sign letter of intent for Dupixent across four indications
Sanofi (SNY) announced the successful completion of negotiations between the pan-Canadian Pharmaceutical Alliance and Sanofi with a signed Letter of Intent for Dupixent for four additional indications...
Recursion To Receive $10 Mln Milestone Payment As Sanofi Selects Immunology Drug Candidate
(RTTNews) - Recursion Pharmaceuticals Inc. (RXRX) announced Thursday that Sanofi (SNY) has selected the first development candidate under their research collaboration, triggering a $10 million milesto...
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT, Oct. 15...
European Commission Accepts Makes Sanofi's Commitments Legally Binding On Flu Vaccine Practices
(RTTNews) - Wednesday, the European Commission has made commitments offered by Sanofi (SNY) legally binding under EU antitrust rules.
Sanofi (SNY) Avoids EU Fine with Commitments on Vaccine Marketing Practices
Sanofi (SNY) Avoids EU Fine with Commitments on Vaccine Marketing Practices
Sanofi Resolves EU Antitrust Investigation with Binding Commitments
Sanofi Resolves EU Antitrust Investigation with Binding Commitments
European Commission Enforces Sanofi's Commitments on Antitrust Concerns (SNY)
European Commission Enforces Sanofi's Commitments on Antitrust Concerns (SNY)
EU accepts Sanofi’s concessions to end probe over vaccine marketing
The European Commission has made commitments offered by Sanofi (SNY) legally binding under EU antitrust rules. The commitments relate to the Commission’s preliminary competition concerns relating to S...
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
Sanofi's offer to rectify the potential effects of its past messages on a rival flu shot awould address concerns, the bloc's executive arm said.
Regeneron (REGN) Reports Q3 R&D Charge Amid $8B Immunology Deal Expansion with Sanofi
Regeneron (REGN) Reports Q3 R&D Charge Amid $8B Immunology Deal Expansion with Sanofi
Sanofi: Availability of the aide-mémoire for Q3 2026 results
Availability of the aide-mémoire for Q3 2026 results Paris, France - October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sano...
Press Release : Availability of the aide-mémoire for Q3 2026 results
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi....
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict l...
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people...
Sanofi SA and Regeneron Investor Event Transcript
Sanofi SA and Regeneron Investor Event Transcript
Regeneron price target raised to $930 from $870 at Jefferies
Jefferies raised the firm’s price target on Regeneron (REGN) to $930 from $870 and keeps a Buy rating on the shares. The company’s expanded collaboration with Sanofi (SNY) on four…
Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (SNY) enhances both companies’ ability to capitalize…
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, addi...
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the block...
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory ...
Sanofi Transcript: Collaboration
The expanded alliance adds four long-acting antibody programs, with a pivotal-study start for the lead IL-13 asset expected in late 2027 or early 2028. Partners will share development costs and global profits 50/50, with a decision on lunsekimig to follow COPD data.
Sanofi Press release: Collaboration
Sanofi issued a press release on October 1, 2026, disclosing material business information to investors.